Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
Authors
Keywords
Bladder cancer, Epidemiology, Meta-analysis, Pioglitazone, Rosiglitazone, Thiazeolidinedione
Journal
DIABETOLOGIA
Volume 58, Issue 3, Pages 493-504
Publisher
Springer Nature
Online
2014-12-08
DOI
10.1007/s00125-014-3456-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Review on Thiazolidinediones and Bladder Cancer in Human Studies
- (2014) Chin-Hsiao Tseng JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS
- Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer
- (2014) James D. Lewis et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use
- (2014) Victoriano Romero et al. BMC Urology
- Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis
- (2013) Richard M. Turner et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Rosiglitazone is not associated with an increased risk of bladder cancer
- (2013) Chin-Hsiao Tseng Cancer Epidemiology
- Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies
- (2013) M. Ferwana et al. DIABETIC MEDICINE
- Risk of Bladder Cancer in Diabetic Patients Treated with Rosiglitazone or Pioglitazone: A Nested Case–Control Study
- (2013) Fei-Yuan Hsiao et al. DRUG SAFETY
- Pioglitazone use and the risk of bladder cancer
- (2013) Hsin-Wei Kuo et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Pioglitazone and bladder cancer: a propensity score matched cohort study
- (2012) Li Wei et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis
- (2012) I. N. Colmers et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Metformin and the Risk of Cancer: Time-related biases in observational studies
- (2012) S. Suissa et al. DIABETES CARE
- Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis
- (2012) Zhaowei Zhu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes
- (2012) Kanta Fujimoto et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
- (2012) A. Neumann et al. DIABETOLOGIA
- Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
- (2012) H. M. Colhoun et al. DIABETOLOGIA
- The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
- (2012) L. Azoulay et al. BMJ-British Medical Journal
- The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
- (2012) Sun Ok Song et al. Diabetes & Metabolism Journal
- Pioglitazone and Bladder Cancer: A population-based study of Taiwanese
- (2011) C.-H. Tseng DIABETES CARE
- Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study
- (2011) J. D. Lewis et al. DIABETES CARE
- Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
- (2011) C. Piccinni et al. DIABETES CARE
- Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan
- (2011) C.-H. Tseng DIABETOLOGIA
- Pioglitazone and bladder cancer – Authors' reply
- (2011) Erland Erdmann et al. LANCET
- Diabetes and risk of bladder cancer
- (2010) Todd MacKenzie et al. CANCER
- Effects of Pioglitazone, a Peroxisome Proliferator–Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat
- (2009) Shugo Suzuki et al. TOXICOLOGICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More